About the company

Delgen Biosciences was founded in 2020 by a team of seasoned scientists in new drug development, polymer chemistry, and nanomaterials. By harnessing their expertise, the founders set out to pursue their ambition to develop the next-generation drug delivery technology, which has the potential to become an alternative therapeutic modality for the future precision medicine. Our initial product is an ophthalmic drug for the benefit of millions of age-related macular degeneration (AMD) patients.

Our research is made possible by the following grants

National Institutes of Health

Small Business Innovation Research

One North Carolina

Small Business Matching Fund

University of North Carolina

KickStart Commercialization Grant Award